NCT02573064 is a clinical trial of Colistin in Acinetobacter Infections, sponsored by Maimónides Biomedical Research Institute of Córdoba.

Who is sponsoring NCT02573064?

NCT02573064 is sponsored by Maimónides Biomedical Research Institute of Córdoba.

What drugs are being tested in NCT02573064?

Interventions in NCT02573064: Colistin, Tigecycline, Vancomycin.

What condition does NCT02573064 study?

NCT02573064 studies Acinetobacter Infections.

Is NCT02573064 still recruiting?

NCT02573064 is currently completed. Last updated 8 October 2015.

Last reviewed 2015-10-08 · How we verify

NCT02573064

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Treatment With Colistin on Mortality Bacteremia Multiresistant Acinetobacter Baumannii Sensitive Colistin in Patients Critical

Completed Last updated 8 October 2015

What this trial tests

trial testing Colistin in Acinetobacter Infections in 113 participants. Completed.

Timeline

1 January 2010

Primary endpoint
1 December 2012

Quick facts

Lead sponsor	Maimónides Biomedical Research Institute of Córdoba
Status	Completed
Study type	OBSERVATIONAL
Enrollment	113
Start date	1 January 2010
Primary completion	1 December 2012

Drugs / interventions tested

Colistin (COLISTIN) — full drug profile →
Tigecycline (TIGECYCLINE) — full drug profile →
Vancomycin (vancomycin) — full drug profile →

Conditions studied

Acinetobacter Infections — all drugs for Acinetobacter Infections →

Sponsor

Maimónides Biomedical Research Institute of Córdoba

Who can join

16 and older, any sex, with Acinetobacter Infections. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

All-cause 30-day mortality (crude).
Time frame: 30 days

Sponsor's own description

The present study was designed to study the impact of empirical treatment with colistin empirical monotherapy and combined treatment with tigecycline and vancomycin on mortality of bacteremia Multiresistant Acinetobacter Baumannii . The main objective was to evaluate the efficacy of empirical treatment with colistin and combined targeted therapy. The different therapeutical interventions were administered following the routine clinical practice in the medical centre and the investigator did not assign specific interventions to the subjects of the study.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Review: Lessons Learned From Clinical Trials Using Antimicrobial Peptides (AMPs).
Dijksteel GS, Ulrich MMW, Middelkoop E, Boekema BKHL. · · 2021 · cited 260× · PMID 33692766 · DOI 10.3389/fmicb.2021.616979
Design methods for antimicrobial peptides with improved performance.
Mwangi J, Kamau PM, Thuku RC, Lai R. · · 2023 · cited 60× · PMID 37914524 · DOI 10.24272/j.issn.2095-8137.2023.246
The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii.
Amat T, Gutiérrez-Pizarraya A, Machuca I, Gracia-Ahufinger I, et al · · 2018 · cited 39× · PMID 28970161 · DOI 10.1016/j.cmi.2017.09.016
Are Antimicrobial Peptides a 21st-Century Solution for Atopic Dermatitis?
Machado M, Silva S, Costa EM. · · 2023 · cited 6× · PMID 37686269 · DOI 10.3390/ijms241713460

Verify or expand the search:

Other trials of Colistin

Trials testing the same drug.

NCT07326540 — Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients W · Phase 3 · not yet recruiting
NCT05586815 — Efficacy of Colistin Monotherapy Versus Colistin Plus Minocycline for Carbapenem-Resistant A. Baumannii Infection · Phase 4 · unknown
NCT05613361 — The Effect of Curcumin Against Colistin-induced Nephrotoxicity · Phase 3 · unknown
NCT05542446 — Pharmacokinetics of Colistin in Critically Ill Patients With Extracorporeal Membrane Oxygenation · Phase 4 · terminated
NCT05258851 — Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections · Phase 3 · terminated

Other Maimónides Biomedical Research Institute of Córdoba trials

Trials by the same sponsor.

NCT06783491 — Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Ad · Phase 3 · not yet recruiting
NCT07479303 — Vitamin D Status in Young Medical Residents · completed
NCT07178379 — Hysteroscopy Anesthesia for Relief of Pain · NA · not yet recruiting
NCT06712485 — Biomarkers in EV Associated With Marrow Adiposity in Anorexia · not yet recruiting
NCT06579846 — 12-Month Efficacy of Exercise and Cytisinicline for Tobacco Abstinence · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02573064 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Maimónides Biomedical Research Institute of Córdoba
Last refreshed: 8 October 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02573064.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing